Toripalimab in Combination With Platinum Plus Etoposidein Patients With Extensive-Stage Small Cell Lung Cancer

Phase 3

Completed

• Conditions: Small Cell Lung Cancer
• Interventions: Drug: TORIPALIMAB INJECTION(JS001 ) Carboplatin Cisplatin Etoposide Placebo

• Registration Number: NCT04012606
• Lead Sponsor: Shanghai Junshi Bioscience Co., Ltd.

Brief Summary

This is a phase III, multicenter, double-blinded, placebo-controlled study of platinum（Cisplatin or Carboplatin） plus etoposide with or without toripalimab as first Line therapy in patients with extensive stage small cell lung cancer.

The purpose of this study is to evaluate the safety and efficacy of toriplimab in combination with platinum（Cisplatin or Carboplatin） plus etoposide in treatment naive extensive stage small cell lung cancer.

Participants will receive asigned study treatment until progressive disease (PD) as assessed by the investigator using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1).

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-07-05
• Study First Submitted QC: 2019-07-08
• Study First Posted: 2019-07-09
• Study Start: 2019-07-23
• Primary Completion: 2023-04-20
• Study Completion: 2023-04-20
• Status Verified: 2025-01
• Last Update Submitted: 2025-01-14
• Last Update Posted: 2025-01-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 442

Inclusion Criteria

1. ≥18 years , male or female;
2. Histologically or cytologically confirmed ES-SCLC (per the Veterans Administration Lung Study Group (VALG) staging system
3. ECOG PS 0~1;
4. No prior treatment or immunocheckpoint inhibitors for ES-SCLC;
5. Treatment-free for at least 6 months since last chemo/radiotherapy, among those treated (with curative intent) with prior chemo/radiotherapy for limited-stage SCLC；
6. Patients with asymptomatic brain metastases who have received previous treatment
7. Has provided tumor tissue samples
8. Estimated survival time ≥8 weeks;
9. There is at least one measurable lesion that conforms to RECIST criteria v1.1.For lesions that have received previous radiation therapy, the lesion can only be included in the measurable lesion if the disease progression is clear after radiotherapy and the lesion is not the only measurable lesion.
10. Before the first dose of the study drug, it should have appropriate organ function, and the laboratory test value should meet the protocol.
11. Has adequate hematologic and end organ function

Exclusion Criteria

1. Prior systemtic treatment for ES-SCLC;
2. Prior treatment with any CD137 agnist or immunocheckpoint inhibitors.
3. Subjects with active or untreated central nervous system (CNS) tumor metastasis;
4. Spinal cord compression not definitively treated with surgery and/or radiation or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for ≥ 1 week prior to randomization
5. Cancerous meningitis;
6. Uncontrolled or symptomatic hypercalcemia;
7. Other malignant tumors within 5 years prior to the first dose of study treatment
8. Subjects with any active, known or suspected autoimmune disease;
9. History of idiopathic pulmonary fibrosis, drug-induced pneumonitis,or evidence of active pneumonitis .
10. Subjects who received major surgery within 28 days prior to enrollment or were not fully recovered from prior surgery;
11. Significant cardiovascular disease, such as New York Heart Assoc

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
TORIPALIMAB	TORIPALIMAB INJECTION(JS001 ) Carboplatin Cisplatin Etoposide Placebo	-
Chemotherapy	TORIPALIMAB INJECTION(JS001 ) Carboplatin Cisplatin Etoposide Placebo	-

Primary Outcome Measures

Name	Time	Method
PFS (Progression Free Survival) by investigator	Approximately 2 years	Progression free survival (PFS) evaluated by investigators according to the response evaluation criteria in solid tumors (RECIST 1.1)
Overall suvival (OS)	Approximately 2.8 years	Overall suvival (OS)

Secondary Outcome Measures

Name	Time	Method
DOR (Duration of Response)	Approximately 2 years	Duration of response (DOR) evaluated by investigators and BIRC based on RECIST1.1;
ORR (Objective Response Rate)	Approximately 2 years	Objective response rate (ORR) evaluated by investigators and BIRC based on RECIST1.1;
PFS (Progression Free Survival) per RECIST1.1 as Assessed by BIRC (Blinded Independent Review Board）	Approximately 2 years	PFS evaluated by the Blinded Individual Review Committee (BIRC) based on RECIST1.1 criteria;
TTR (Time to Response)	Approximately 2 years	Time to response (TTR) evaluated by investigators and BIRC based on RECIST1.1;
DCR (Disease of Response)	Approximately 2 years	Disease control rate (DCR) evaluated by investigators and BIRC based on RECIST1.1;
OS (Overall Survival) rate	Approximately 2 years	OS rates at 1 and 2 years
Incidence of AEs/SAEs	Approximately 2 years	Adverse events (AEs) ; serious adverse events (SAEs); abnormal value of Lab test according to NCI-CTCAE V5.0
PFS (Progression Free Survival) Rate	Approximately 1year	PFS rates at 6-month（inestigators and BICR） and at 1-year

Trial Locations

Locations (1)

Ying Cheng; 🇨🇳 Chang chun, China